{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:00:46Z","timestamp":1758970846399},"reference-count":15,"publisher":"FapUNIFESP (SciELO)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Neuro-Psiquiatr."],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:p>Objective Analyze the demographics, clinical characteristics, efficacy and safety of natalizumab treatment in Brazilian patients with multiple sclerosis (MS) followed up for at least 12 months, in two tertiary MS care centers in S\u00e3o Paulo.Method We evaluated the effect of natalizumab treatment on annualized relapse rate and disability progression in 75 patients with MS treated with natalizumab for at least 12 months. A subgroup analysis was performed to evaluate efficacy of natalizumab treatment in patients with Expanded Disability Status Scale (EDSS) \u2264 3.0 vs patients with EDSS &gt; 3.Results Patients treated for at least one year with natalizumab showed a 91% reduction in aRR, as well and an improvement in neurological disability. The impact of natalizumab treatment was greater in patients with EDSS &lt; 3.0. Overall, natalizumab was safe but one patient developed progressive multifocal leukoencephalopathy.Conclusion Natalizumab as a third line therapy is safe and efficacious, especially in patients with mild neurological disability.<\/jats:p>","DOI":"10.1590\/0004-282x20150098","type":"journal-article","created":{"date-parts":[[2015,9,2]],"date-time":"2015-09-02T19:10:44Z","timestamp":1441221044000},"page":"736-740","source":"Crossref","is-referenced-by-count":5,"title":["Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers"],"prefix":"10.1590","volume":"73","author":[{"given":"Enedina Maria Lobato de","family":"Oliveira","sequence":"first","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata Faria","family":"Simm","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gorana","family":"Dasic","sequence":"additional","affiliation":[{"name":"Biogen Idec Inc,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00edlia Mamprim de","family":"Morais","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samira Luiza dos Apostolos","family":"Perreira","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagoberto","family":"Callegaro","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"issue":"10","key":"ref1","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrneurol.2009.139","article-title":"Predicting responders to therapies for multiple sclerosis","volume":"5","author":"R\u00edo J","year":"2009","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"ref2","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman CH","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"ref3","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrneurol.2010.164","article-title":"Progressive multifocal leukoencephalopathy and other forms of JC virus disease","volume":"6","author":"Brew BJ","year":"2010","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1468-1331.2009.02728.x","article-title":"Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries","volume":"17","author":"Putzki N","year":"2010","journal-title":"Eur J Neurol"},{"issue":"2","key":"ref5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016664","article-title":"Switching multiple sclerosis patients with breakthrough disease to second-line therapy","volume":"6","author":"Castillo-Trivino T","year":"2011","journal-title":"PLoS One"},{"issue":"9","key":"ref6","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1007\/s00415-012-6414-9","article-title":"Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study","volume":"259","author":"Fern\u00e1ndez O","year":"2012","journal-title":"J Neurol"},{"issue":"6","key":"ref7","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria\u201d","volume":"58","author":"Polman CH","year":"2005","journal-title":"Ann Neurol"},{"issue":"5","key":"ref8","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/1352458508101935","article-title":"Neuromyelitis optica in Brazil: a study on clinical and prognostic factors","volume":"15","author":"Bichuetti DB","year":"2009","journal-title":"Mult Scler"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1352458511435105","article-title":"Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab","volume":"18","author":"S\u00f8rensen PS","year":"2012","journal-title":"Mult Scler"},{"issue":"3","key":"ref10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00415-009-0093-1","article-title":"The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL","volume":"256","author":"Hutchinson M","year":"2009","journal-title":"J Neurol"},{"issue":"8","key":"ref11","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1177\/1352458511399611","article-title":"Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis","volume":"17","author":"Phillips JT","year":"2011","journal-title":"Mult Scler"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1474-4422(09)70021-3","article-title":"Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study","volume":"8","author":"Havrdova E","year":"2009","journal-title":"Lancet Neurol"},{"issue":"3","key":"ref13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1590\/S0004-282X2013000300002","article-title":"Natalizumab adverse events are rare in patients with multiple sclerosis","volume":"71","author":"Fragoso YD","year":"2013","journal-title":"Arq Neuropsiquiatr"},{"issue":"11","key":"ref14","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458513477925","article-title":"Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort","volume":"19","author":"Olsson T","year":"2013","journal-title":"Mult Scler"},{"key":"ref15","series-title":"DATASUS- Portal da S\u00e1ude \u2013 Minist\u00e9rioa da S\u00e1ude"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/anp\/v73n9\/0004-282X-anp-73-9-0736.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T23:48:52Z","timestamp":1495496932000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-282X2015000900736&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0004-282X2015000900736"],"URL":"https:\/\/doi.org\/10.1590\/0004-282x20150098","relation":{},"ISSN":["0004-282X"],"issn-type":[{"value":"0004-282X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}